Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
Amy E. Colson, Princy Kumar, Peter Ruane, Ploenchan Chetchotisakd et autres